<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Avian influenza: Treatment and prevention</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Avian influenza: Treatment and prevention</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Avian influenza: Treatment and prevention</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Iain Stephenson, MD, FRCP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin S Hirsch, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elinor L Baron, MD, DTMH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 03, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1575094619"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The treatment and prevention of avian influenza infection will be reviewed here [<a href="#rid1">1</a>]. </p><p>The epidemiology, clinical manifestations, and diagnosis of avian influenza infection are discussed separately, as are issues related to avian influenza vaccines. (See  <a class="medical medical_review" href="/z/d/html/7002.html" rel="external">"Avian influenza: Epidemiology and transmission"</a> and  <a class="medical medical_review" href="/z/d/html/7001.html" rel="external">"Avian influenza: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/7000.html" rel="external">"Avian influenza vaccines"</a>.)</p><p>Issues related to treatment and prevention of seasonal influenza are also discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6998.html" rel="external">"Seasonal influenza in nonpregnant adults: Treatment"</a> and  <a class="medical medical_review" href="/z/d/html/7017.html" rel="external">"Seasonal influenza in adults: Role of antiviral prophylaxis for prevention"</a> and  <a class="medical medical_review" href="/z/d/html/7007.html" rel="external">"Seasonal influenza vaccination in adults"</a>.)</p><p class="headingAnchor" id="H1285623340"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H131522541"><span class="h2">Clinical approach</span><span class="headingEndMark"> — </span>Our approach to treatment of avian influenza is in keeping with the guidance of the United States Centers for Disease Control and Prevention [<a href="#rid2">2</a>]. </p><p>Antiviral treatment should be administered for all confirmed human cases of avian influenza, as well as probable and suspected cases. Data regarding efficacy of treatment are discussed below. Case definitions are outlined separately. (See <a class="local">'Efficacy'</a> below and  <a class="medical medical_review" href="/z/d/html/7001.html" rel="external">"Avian influenza: Clinical manifestations and diagnosis", section on 'Case definitions'</a>.)</p><p>Laboratory testing and initiation of antiviral treatment should occur simultaneously; treatment should <strong>not</strong> be delayed for laboratory confirmation of avian influenza virus infection. Diagnostic tools are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7001.html" rel="external">"Avian influenza: Clinical manifestations and diagnosis", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H3970989204"><span class="h3">Site of care</span><span class="headingEndMark"> — </span>Hospitalization is warranted for patients with significant dehydration and for severely ill patients, especially those with respiratory distress, hypoxemia, impaired cardiopulmonary function, or altered mental status. In the absence of these findings, admission for observation may be warranted for patients with increased risk for complications  (<a class="graphic graphic_table graphicRef72029" href="/z/d/graphic/72029.html" rel="external">table 1</a>).</p><p>Infection prevention and control measures should be implemented for patients with known or suspected avian influenza. (See <a class="local">'Infection control'</a> below.)</p><p class="headingAnchor" id="H1849911937"><span class="h3">Timing of treatment</span><span class="headingEndMark"> — </span>Antiviral treatment should be administered for all confirmed, probable, and suspected cases of avian influenza. We administer antiviral treatment as early as possible; treatment should be initiated even if more than 48 hours have elapsed since illness onset. Treatment is especially important for individuals at increased risk for influenza complications  (<a class="graphic graphic_table graphicRef72029" href="/z/d/graphic/72029.html" rel="external">table 1</a>). </p><p>For outpatients with uncomplicated disease in whom fever is absent and symptoms are nearly resolved, the decision to initiate antiviral treatment should be made on a case-by-case basis. Individuals who are not treated with antiviral medications should be closely monitored for progression of illness.</p><p>Data regarding timing of treatment are discussed below. (See <a class="local">'Efficacy'</a> below.)</p><p class="headingAnchor" id="H261800802"><span class="h3">Antiviral selection</span></p><p class="headingAnchor" id="H40256619"><span class="h4">Hospitalized patients</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preferred regimen</strong> − Oral <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">oseltamivir</a> is the preferred regimen for treatment of avian influenza in hospitalized patients. Use of this agent for treatment of avian influenza is extrapolated from clinical data and experience with oseltamivir for treatment of seasonal influenza. (See  <a class="medical medical_review" href="/z/d/html/6998.html" rel="external">"Seasonal influenza in nonpregnant adults: Treatment"</a>.)</p><p></p><p class="bulletIndent1">The standard adult treatment course consists of 75 mg twice daily for five days; however, the optimal duration for patients with severe disease is uncertain. Among hospitalized patients with avian influenza virus infection, higher virus levels and longer duration of viral replication (particularly in the lower respiratory tract) have been observed compared with seasonal influenza virus infection [<a href="#rid3">3-7</a>].</p><p></p><p class="bulletIndent1">Therefore, for hospitalized patients with severe and prolonged illness, reverse transcription polymerase chain reaction testing of lower respiratory tract specimens should be used in conjunction with clinical judgment to guide decisions regarding treatment duration (extension up to 10 days). In addition, an extended treatment course might be warranted in severely immunocompromised patients (such as hematopoietic stem cell transplant recipients) who may have prolonged viral replication. </p><p></p><p class="bulletIndent1">There is no role for increasing the <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">oseltamivir</a> dose, given lack of benefit [<a href="#rid8">8-10</a>]. In addition, thus far, clinical data do not support use of combination antiviral therapy for treatment of avian influenza [<a href="#rid11">11</a>] or seasonal influenza [<a href="#rid12">12</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alternative regimens</strong> − Alternative antiviral agents include <a class="drug drug_general" data-topicid="9527" href="/z/d/drug information/9527.html" rel="external">peramivir</a> or <a class="drug drug_general" data-topicid="10323" href="/z/d/drug information/10323.html" rel="external">zanamivir</a> (both administered parenterally):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9527" href="/z/d/drug information/9527.html" rel="external">Peramivir</a> − Peramivir may be used for patients who cannot tolerate oral therapy; while peramivir has been approved by the US Food and Drug Administration (FDA) for treatment of uncomplicated seasonal influenza, we think its use is reasonable for patients with severe avian influenza who cannot tolerate oral agents. In such cases, we favor adult dosing of 600 mg intravenously once daily for five days (rather than a single dose). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10323" href="/z/d/drug information/10323.html" rel="external">Zanamivir</a> − In regions where parenteral zanamivir is available (eg, the United Kingdom and the European Union), this agent may be used if other antiviral agents cannot be used. The usual duration of treatment for parenteral zanamivir is 5 to 10 days. Inhaled zanamivir should not be used for treatment of severe avian influenza given limited efficacy data for treatment of severe seasonal influenza.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="119458" href="/z/d/drug information/119458.html" rel="external">Baloxavir</a> is FDA approved for the treatment of uncomplicated seasonal influenza; however, given limited efficacy data for treatment of severe seasonal influenza [<a href="#rid13">13,14</a>], baloxavir is not a preferred agent for treatment of hospitalized patients with avian influenza. However, inhibitory effects of baloxavir against influenza A(H7N9) have been observed in animals and in vivo cell models [<a href="#rid15">15,16</a>].</p><p></p><p class="headingAnchor" id="H1206676493"><span class="h4">Outpatients</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preferred regimen</strong> − <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">Oseltamivir</a> (adult dose: 75 mg orally twice daily for five days) is the preferred regimen for treatment of avian influenza in outpatients, regardless of time since symptom onset [<a href="#rid2">2</a>]. Use of this agent for treatment of avian influenza is extrapolated from clinical data and experience with oseltamivir for treatment of seasonal influenza. (See  <a class="medical medical_review" href="/z/d/html/6998.html" rel="external">"Seasonal influenza in nonpregnant adults: Treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alternative regimens</strong> − Alternative antiviral agents for outpatients with uncomplicated mild-to-moderate illness presenting within 48 hours of symptom onset include <a class="drug drug_general" data-topicid="10323" href="/z/d/drug information/10323.html" rel="external">zanamivir</a> (inhaled), <a class="drug drug_general" data-topicid="9527" href="/z/d/drug information/9527.html" rel="external">peramivir</a> (parenteral), or <a class="drug drug_general" data-topicid="119458" href="/z/d/drug information/119458.html" rel="external">baloxavir</a> (oral):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10323" href="/z/d/drug information/10323.html" rel="external">Zanamivir</a> (for patients ≥7 years of age: 10 mg [2 inhalations] twice daily for five days); inhaled zanamivir is contraindicated in patients with asthma or chronic obstructive pulmonary disease</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9527" href="/z/d/drug information/9527.html" rel="external">Peramivir</a> (for patients ≥13 years of age: 600 mg intravenously as a single dose; for patients 6 months to 12 years of age: 12 mg/kg intravenously as a single dose [maximum dose 600 mg]) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="119458" href="/z/d/drug information/119458.html" rel="external">Baloxavir</a> (for patients ≥12 years of age; 40 to 80 kg: 40 mg orally as a single dose; ≥80 kg: 80 mg orally as a single dose) [<a href="#rid17">17</a>] </p><p></p><p class="headingAnchor" id="H507339108"><span class="h2">Patients with persistent symptoms</span></p><p class="headingAnchor" id="H175007192"><span class="h3">Evaluation and treatment for bacterial infection</span><span class="headingEndMark"> — </span>The approach to diagnostic evaluation for and empiric treatment of bacterial infection for patients with influenza is described separately. (See  <a class="medical medical_review" href="/z/d/html/6998.html" rel="external">"Seasonal influenza in nonpregnant adults: Treatment", section on 'Concomitant infection'</a>.)</p><p class="headingAnchor" id="H926698661"><span class="h3">Antiviral resistance</span><span class="headingEndMark"> — </span>Antiviral resistance should be considered in patients treated with <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">oseltamivir</a> and/or <a class="drug drug_general" data-topicid="9527" href="/z/d/drug information/9527.html" rel="external">peramivir</a> with progressive lower respiratory tract disease [<a href="#rid5">5,18-21</a>]. The emergence of oseltamivir-resistant viruses containing an H275Y mutation in viral neuraminidase has been reported during oseltamivir treatment of patients with H5N1 avian influenza infection [<a href="#rid5">5,18</a>]. Similarly, the emergence of H7N9 viruses with an R292K mutation in viral neuraminidase confers resistance to neuraminidase inhibitors [<a href="#rid3">3,22-24</a>]; this mutation confers high-level resistance to oseltamivir and moderately decreased sensitivity to peramivir and <a class="drug drug_general" data-topicid="10323" href="/z/d/drug information/10323.html" rel="external">zanamivir</a>.</p><p>In the setting of suspected <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">oseltamivir</a> and/or <a class="drug drug_general" data-topicid="9527" href="/z/d/drug information/9527.html" rel="external">peramivir</a> resistance, <a class="drug drug_general" data-topicid="10323" href="/z/d/drug information/10323.html" rel="external">zanamivir</a> (administered parenterally, if feasible) is the preferred treatment; <a class="drug drug_general" data-topicid="119458" href="/z/d/drug information/119458.html" rel="external">baloxavir</a> may be an acceptable alternative treatment. Consultation with United States Centers for Disease Control and Prevention (CDC) Influenza Division via the CDC Emergency Operations Center (770-488-7100) should also be pursued to arrange testing for antiviral resistance; some avian influenza viruses develop oseltamivir and peramivir resistant while retaining susceptibility to zanamivir and baloxavir.</p><p>Issued related to antiviral resistance are discussed further separately. (See  <a class="medical medical_review" href="/z/d/html/6998.html" rel="external">"Seasonal influenza in nonpregnant adults: Treatment"</a>.)</p><p class="headingAnchor" id="H3372785135"><span class="h2">Antiviral agents</span></p><p class="headingAnchor" id="H3254687211"><span class="h3">Drug classes</span><span class="headingEndMark"> — </span>Classes of antiviral drugs for treatment of influenza include the neuraminidase inhibitors (<a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">oseltamivir</a>, <a class="drug drug_general" data-topicid="10323" href="/z/d/drug information/10323.html" rel="external">zanamivir</a>, and <a class="drug drug_general" data-topicid="9527" href="/z/d/drug information/9527.html" rel="external">peramivir</a>), a selective inhibitor of influenza cap-dependent endonuclease (<a class="drug drug_general" data-topicid="119458" href="/z/d/drug information/119458.html" rel="external">baloxavir</a>), and the adamantanes (<a class="drug drug_general" data-topicid="8508" href="/z/d/drug information/8508.html" rel="external">amantadine</a> and <a class="drug drug_general" data-topicid="9866" href="/z/d/drug information/9866.html" rel="external">rimantadine</a>, also known as M2 ion channel inhibitors). </p><p>The neuraminidase inhibitors are the mainstay of treatment. <a class="drug drug_general" data-topicid="119458" href="/z/d/drug information/119458.html" rel="external">Baloxavir</a> has activity against influenza A and B viruses and has been approved in Japan and the United States for the treatment of uncomplicated seasonal influenza; however, thus far, there is no clinical experience with use of this drug for treatment of avian influenza in humans. Adamantanes should <strong>not</strong> be used for the treatment of influenza due to emergence of high rates of resistance among influenza A viruses. </p><p>Antiviral agents are discussed further separately. (See  <a class="medical medical_review" href="/z/d/html/6998.html" rel="external">"Seasonal influenza in nonpregnant adults: Treatment", section on 'Antiviral agents'</a>.)</p><p class="headingAnchor" id="H3506304016"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>The approach to antiviral selection for treatment of avian influenza described above is based largely on efficacy data for treatment of seasonal influenza, in addition to observational case series of patients with avian influenza [<a href="#rid25">25-29</a>]. (See  <a class="medical medical_review" href="/z/d/html/6998.html" rel="external">"Seasonal influenza in nonpregnant adults: Treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Benefit of antiviral treatment</strong> – In a 2010 registry analysis including more than 300 patients with avian influenza A(H5N1), those who were treated with <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">oseltamivir</a> had lower mortality than those who received no antiviral treatment (hazard ratio 0.51, 95% CI 0.34-0.77) [<a href="#rid25">25</a>]. The mortality benefit was greatest when treatment was started within the first two days following symptom onset but some benefit persisted for up to six to eight days following symptom onset. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timing of antiviral treatment</strong> – In a 2018 study including 160 patients hospitalized with avian influenza A(H7N9) infection, patients who received treatment with a neuraminidase inhibitor within two days of symptom onset had lower mortality compared with those who received treatment within two to five days or after five days (15, 23, and 37 percent, respectively) [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent1">In a 2012 registry study including 215 patients with avian influenza A(H5N1) infection, the case-fatality rate was lower among those who received <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">oseltamivir</a> treatment within two days of symptom onset than among those who received treatment later (18 versus 63 percent) [<a href="#rid29">29</a>]. In another study including 193 children with avian influenza A(H5N1) infections, there was an increased risk of death for each day of delay in initiating oseltamivir (odds ratio 1.75, 95% CI 1.17-2.61) [<a href="#rid31">31</a>].</p><p></p><p class="headingAnchor" id="H4018629728"><span class="h3">Adverse effects</span><span class="headingEndMark"> — </span>Adverse effects of antiviral drugs for treatment of influenza are described separately. (See  <a class="medical medical_review" href="/z/d/html/6998.html" rel="external">"Seasonal influenza in nonpregnant adults: Treatment", section on 'Antiviral efficacy and adverse effects'</a>.)</p><p class="headingAnchor" id="H227581157"><span class="h2">Investigational approaches</span></p><p class="bulletIndent1"><span class="glyph">●</span>Convalescent plasma – No conclusions can be made on the clinical benefit of convalescent plasma treatment from limited uncontrolled data [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Glucocorticoids – Glucocorticoids should not be used as adjunctive therapy for treatment of patients with avian influenza in the absence of a separate indication for their use. Observational studies have suggested an increased mortality risk and increased duration of virus shedding among patients with avian influenza treated with glucocorticoids [<a href="#rid32">32-34</a>].</p><p></p><p class="headingAnchor" id="H2467309378"><span class="h2">Outcomes</span><span class="headingEndMark"> — </span>Few studies have assessed long-term clinical follow-up of survivors of severe or illness due to avian influenza A virus infection. </p><p class="bulletIndent1"><span class="glyph">●</span>In one analysis using China's national integrated database to evaluate approximately 130 cases of laboratory-confirmed avian influenza A H7N9 requiring hospitalization, the estimated fatality risk on hospital admission was 36 percent (compared with 70 percent for avian influenza A H5N1) [<a href="#rid35">35,36</a>]. The fatality risk was substantially higher for individuals ≥60 years of age compared with younger individuals (49 versus 18 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A cohort study including 56 adults with H7N9 avian influenza followed for two years reported that pulmonary function and chest computed tomography findings improved by six months after hospital discharge and most had returned to work; however, most patients had persistent abnormalities [<a href="#rid37">37</a>]. At one year after discharge, 42 percent had pulmonary fibrosis and 52 percent had parenchymal opacities, with bronchiectasis noted in 24 percent and pleural thickening reported in 22 percent.</p><p></p><p class="headingAnchor" id="H2211147345"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>Tools for prevention of avian influenza include infection control, postexposure prophylaxis, and vaccine development. There is no role for routine pre-exposure prophylaxis.</p><p class="headingAnchor" id="H3448112842"><span class="h2">Infection control</span></p><p class="headingAnchor" id="H477576916"><span class="h3">Health care facilities</span><span class="headingEndMark"> — </span>Infection control measures to reduce the risk of nosocomial transmission include negative pressure respiratory isolation with standard, contact (including eye protection), and airborne (eg, N95 masks) precautions for health care personnel [<a href="#rid38">38</a>]. These precautions are described further separately. (See  <a class="medical medical_review" href="/z/d/html/4042.html" rel="external">"Infection prevention: Precautions for preventing transmission of infection"</a>.)</p><p class="headingAnchor" id="H1759560786"><span class="h3">Poultry farms and markets</span><span class="headingEndMark"> — </span>The risk of exposure to avian influenza infection is increased among workers at live-bird markets and individuals involved with bird cleaning, slaughtering, defeathering, or evisceration. </p><p>Avian influenza outbreaks in poultry should prompt surveillance, quarantine, and depopulation (or culling) of affected flocks [<a href="#rid39">39</a>]. Workers involved in control of poultry outbreaks should practice frequent hand hygiene (with soap and water or alcohol-based hand rubs) and adhere to personal protective measures including use of gloves, gowns, N95 masks, and eye protection.</p><p>Measures found to be effective at reducing poultry infection and contamination at live-bird markets include market size reduction, sourcing poultry from local areas, sale of single poultry species, species separation (if multiple species are sold), and attention to sanitation practices [<a href="#rid40">40</a>]. Other proposed measures include vaccination of farm poultry and prohibiting transport of live birds [<a href="#rid41">41-43</a>]. </p><p>Freezing and refrigeration do not substantially reduce the concentration or virulence of viruses in meat, so it is essential to follow safe food-handling procedures and to cook food thoroughly [<a href="#rid39">39,44</a>].</p><p class="headingAnchor" id="H3074308267"><span class="h2">Postexposure prophylaxis</span><span class="headingEndMark"> — </span>The goal of postexposure prophylaxis is to reduce the likelihood of spread of novel influenza A viruses associated with severe illness in humans. The approach outlined below is intended for circumstances in which there are sporadic human cases associated with infected domestic poultry or wild bird exposures, as well as concern for limited, nonsustained human-to-human transmission.</p><p class="headingAnchor" id="H2758479057"><span class="h3">Recipients</span><span class="headingEndMark"> — </span>We administer postexposure prophylaxis to asymptomatic individuals in the following categories [<a href="#rid45">45</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exposure to an infected person</strong> − A person with close (within 2 meters), unprotected (without use of respiratory and eye protection) exposure to a person who is a confirmed, suspected, or probable case of avian influenza virus. Case definitions for confirmed, suspected, or probable cases are outlined separately. (See  <a class="medical medical_review" href="/z/d/html/7001.html" rel="external">"Avian influenza: Clinical manifestations and diagnosis", section on 'Case definitions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exposure to secretions of an infected person</strong> − A person with unprotected contact (without use of respiratory and eye protection) to secretions from a case patient while the case patient was likely infectious (beginning one day prior to symptom onset and continuing until symptoms resolve).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exposure to infected birds</strong> – A person with recent contact (within 10 days of symptom onset), unprotected (without use of respiratory and eye protection), and close exposure (within 2 meters) with sick or dead birds with confirmed avian influenza virus infection by A(H5), A(H7), or A(H9) viruses. These include poultry, wild aquatic birds, or captive birds of prey that have had contact with aquatic birds. Bird exposure includes (1) handling, slaughtering, defeathering, butchering, culling, or preparation of birds for consumption or (2) direct contact with surfaces contaminated by infected bird secretions, excretions, or remains [<a href="#rid46">46</a>].</p><p></p><p>For circumstances in which the optimal approach to postexposure prophylaxis is uncertain, consideration should be given to whether the individual is at increased risk for complications from influenza  (<a class="graphic graphic_table graphicRef72029" href="/z/d/graphic/72029.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H389778663"><span class="h3">Clinical approach</span><span class="headingEndMark"> — </span>Our approach to postexposure prophylaxis is in keeping with the guidance of the United States Centers for Disease Control and Prevention (CDC) [<a href="#rid45">45</a>]. This guidance is based on expert opinion and available data for antiviral treatment and chemoprophylaxis of seasonal, pandemic, and novel influenza A virus infections. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timing</strong> – Administration of postexposure prophylaxis antiviral chemoprophylaxis should begin as soon as possible (ideally within 48 hours) after the exposure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antiviral selection and dosing</strong> – We administer antiviral prophylaxis with one of the following regimens:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">Oseltamivir</a> (adult dosing: 75 mg orally twice daily).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10323" href="/z/d/drug information/10323.html" rel="external">Zanamivir</a> (adult dosing: 10 mg [two 5 mg inhalations] twice daily); inhaled zanamivir is contraindicated in patients with asthma or chronic obstructive pulmonary disease.</p><p></p><p class="bulletIndent1">The above regimens reflect treatment dosing (rather than prophylaxis dosing) used for seasonal influenza. This approach is based on limited data supporting higher prophylaxis dosing in animals for avian influenza A(H5N1) virus infection [<a href="#rid47">47</a>], as well as the desire to reduce the likelihood of emergence of resistance during prophylaxis [<a href="#rid48">48-50</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antiviral duration</strong> – We administer antiviral prophylaxis for 5 or 10 days:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In the setting of time-limited exposure, we continue antiviral prophylaxis for five days from the last known exposure. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In the setting of ongoing exposure (such as in a household setting), we continue antiviral prophylaxis for 10 days, given the potential for prolonged viral shedding from the case patient.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Follow-up</strong> − Close contacts should be monitored daily for 10 days after the last known exposure to a confirmed or probable case; daily assessment should include temperature measurement and evaluation for respiratory symptoms (eg, cough, sore throat, shortness of breath, difficulty breathing).</p><p></p><p class="headingAnchor" id="H490522259"><span class="h3">Individuals who develop symptoms</span><span class="headingEndMark"> — </span>Individuals with temperature ≥38.0°C (≥100.4° F) or any new respiratory symptoms should be referred for prompt evaluation and testing for avian influenza infection. Consultation with CDC Influenza Division via the CDC Emergency Operations Center (770-488-7100) should be pursued to arrange testing for antiviral resistance. In addition, infection prevention and control measures should be implemented. (See <a class="local">'Infection control'</a> above and  <a class="medical medical_review" href="/z/d/html/7001.html" rel="external">"Avian influenza: Clinical manifestations and diagnosis"</a>.)</p><p>For individuals who took <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">oseltamivir</a> prophylaxis for ≥3 days prior to onset of symptoms, oseltamivir should be discontinued as soon as treatment with inhaled <a class="drug drug_general" data-topicid="10323" href="/z/d/drug information/10323.html" rel="external">zanamivir</a> or oral <a class="drug drug_general" data-topicid="119458" href="/z/d/drug information/119458.html" rel="external">baloxavir</a> can be initiated [<a href="#rid45">45</a>]. The rationale for this approach is that novel influenza A viruses may develop oseltamivir resistance (and potentially <a class="drug drug_general" data-topicid="9527" href="/z/d/drug information/9527.html" rel="external">peramivir</a> resistance) but may remain susceptible to zanamivir and baloxavir. Dosing is outlined above. (See <a class="local">'Outpatients'</a> above.)</p><p>For individuals who took <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">oseltamivir</a> prophylaxis for &lt;3 days prior to onset of symptoms, treatment with oseltamivir should be administered for five days; the duration of treatment should be restarted from the day of symptom onset. Dosing is outlined above. (See <a class="local">'Outpatients'</a> above.)</p><p class="headingAnchor" id="H784387039"><span class="h2">Vaccine development</span><span class="headingEndMark"> — </span>Issues related to avian influenza vaccine development are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7000.html" rel="external">"Avian influenza vaccines"</a>.)</p><p class="headingAnchor" id="H1425307180"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/83059.html" rel="external">"Patient education: Bird flu (avian influenza) (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H1160733285"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Site of care</strong> − Hospitalization is warranted for patients with significant dehydration and for severely ill patients, especially those with respiratory distress, hypoxemia, impaired cardiopulmonary function, or altered mental status. In the absence of these findings, admission for observation may be warranted for patients with increased risk for complications  (<a class="graphic graphic_table graphicRef72029" href="/z/d/graphic/72029.html" rel="external">table 1</a>). (See <a class="local">'Site of care'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Antiviral treatment</strong> − We recommend antiviral treatment for patients with confirmed, probable, or suspected avian influenza infection (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). We suggest treatment with <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">oseltamivir</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>); alternative agents and drug dosing are outlined above. Case definitions are outlined separately. (See <a class="local">'Clinical approach'</a> above and <a class="local">'Antiviral selection'</a> above and  <a class="medical medical_review" href="/z/d/html/7001.html" rel="external">"Avian influenza: Clinical manifestations and diagnosis", section on 'Case definitions'</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Timing of treatment</strong> − We administer antiviral treatment as early as possible; treatment should be initiated even if more than 48 hours have elapsed since illness onset. For outpatients with uncomplicated disease in whom fever is absent and symptoms are nearly resolved, the decision to initiate antiviral treatment should be made on a case-by-case basis. (See <a class="local">'Timing of treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Persistent symptoms</strong> – Patients with persistent symptoms warrant evaluation and treatment for bacterial infection. In addition, antiviral resistance should be considered in patients with progressive lower respiratory tract disease treated with <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">oseltamivir</a> and/or <a class="drug drug_general" data-topicid="9527" href="/z/d/drug information/9527.html" rel="external">peramivir</a>. For patients with suspected or known infection due to oseltamivir-resistant virus, we suggest treatment with <a class="drug drug_general" data-topicid="10323" href="/z/d/drug information/10323.html" rel="external">zanamivir</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>) as well as antiviral drug susceptibility testing; <a class="drug drug_general" data-topicid="119458" href="/z/d/drug information/119458.html" rel="external">baloxavir</a> is an alternative treatment. (See <a class="local">'Patients with persistent symptoms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Infection control</strong> (see <a class="local">'Infection control'</a> above)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Health care workers</strong> − Infection control measures to reduce the risk of nosocomial transmission include negative pressure respiratory isolation with standard, contact (gloves, gowns, eye protection), and airborne (eg, N95 masks) precautions for health care personnel. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Poultry workers</strong> − The risk of exposure to avian influenza infection is increased among workers at live bird markets and individuals involved with bird cleaning, slaughtering, defeathering, or evisceration. Such individuals who are involved with poultry outbreaks should adhere to the same personal protective measures used in health care facilities. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Postexposure prophylaxis</strong> − For asymptomatic individuals with exposure to an infected person (or their secretions) or infected birds, we suggest postexposure prophylaxis with <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">oseltamivir</a> or <a class="drug drug_general" data-topicid="10323" href="/z/d/drug information/10323.html" rel="external">zanamivir</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). </p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Uyeki TM, Peiris M. Novel Avian Influenza A Virus Infections of Humans. Infect Dis Clin North Am 2019; 33:907.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Guidance on the use of antiviral medications for treatment of human infections with novel influenza A viruses associated with severe human disease. https://www.cdc.gov/flu/avianflu/novel-av-treatment-guidance.htm (Accessed on June 27, 2022).</li><li><a class="nounderline abstract_t">Hu Y, Lu S, Song Z, et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 2013; 381:2273.</a></li><li><a class="nounderline abstract_t">de Jong MD, Simmons CP, Thanh TT, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 2006; 12:1203.</a></li><li><a class="nounderline abstract_t">de Jong MD, Tran TT, Truong HK, et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005; 353:2667.</a></li><li><a class="nounderline abstract_t">Ho PL, Sin WC, Chan JF, et al. Severe influenza A H7N9 pneumonia with rapid virological response to intravenous zanamivir. Eur Respir J 2014; 44:535.</a></li><li><a class="nounderline abstract_t">Yu L, Wang Z, Chen Y, et al. Clinical, virological, and histopathological manifestations of fatal human infections by avian influenza A(H7N9) virus. Clin Infect Dis 2013; 57:1449.</a></li><li><a class="nounderline abstract_t">Welch SC, Lam SW, Neuner EA, et al. High-dose versus standard dose oseltamivir for treatment of severe influenza in adult intensive care unit patients. Intensive Care Med 2015; 41:1365.</a></li><li><a class="nounderline abstract_t">Pai MP, Lodise TP Jr. Oseltamivir and oseltamivir carboxylate pharmacokinetics in obese adults: dose modification for weight is not necessary. Antimicrob Agents Chemother 2011; 55:5640.</a></li><li><a class="nounderline abstract_t">South East Asia Infectious Disease Clinical Research Network. Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial. BMJ 2013; 346:f3039.</a></li><li><a class="nounderline abstract_t">Wang Y, Guo Q, Yan Z, et al. Factors Associated With Prolonged Viral Shedding in Patients With Avian Influenza A(H7N9) Virus Infection. J Infect Dis 2018; 217:1708.</a></li><li><a class="nounderline abstract_t">Kumar D, Ison MG, Mira JP, et al. Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial. Lancet Infect Dis 2022; 22:718.</a></li><li><a class="nounderline abstract_t">Hayden FG, Sugaya N, Hirotsu N, et al. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. N Engl J Med 2018; 379:913.</a></li><li><a class="nounderline abstract_t">Ison MG, Portsmouth S, Yoshida Y, et al. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis 2020; 20:1204.</a></li><li><a class="nounderline abstract_t">Twabela A, Okamatsu M, Matsuno K, et al. Evaluation of Baloxavir Marboxil and Peramivir for the Treatment of High Pathogenicity Avian Influenza in Chickens. Viruses 2020; 12.</a></li><li><a class="nounderline abstract_t">Taniguchi K, Ando Y, Nobori H, et al. Inhibition of avian-origin influenza A(H7N9) virus by the novel cap-dependent endonuclease inhibitor baloxavir marboxil. Sci Rep 2019; 9:3466.</a></li><li><a class="nounderline abstract_t">Koshimichi H, Ishibashi T, Kawaguchi N, et al. Safety, Tolerability, and Pharmacokinetics of the Novel Anti-influenza Agent Baloxavir Marboxil in Healthy Adults: Phase I Study Findings. Clin Drug Investig 2018; 38:1189.</a></li><li><a class="nounderline abstract_t">Le QM, Kiso M, Someya K, et al. Avian flu: isolation of drug-resistant H5N1 virus. Nature 2005; 437:1108.</a></li><li><a class="nounderline abstract_t">Earhart KC, Elsayed NM, Saad MD, et al. Oseltamivir resistance mutation N294S in human influenza A(H5N1) virus in Egypt. J Infect Public Health 2009; 2:74.</a></li><li><a class="nounderline abstract_t">Baek YH, Song MS, Lee EY, et al. Profiling and characterization of influenza virus N1 strains potentially resistant to multiple neuraminidase inhibitors. J Virol 2015; 89:287.</a></li><li><a class="nounderline abstract_t">Hai R, Schmolke M, Leyva-Grado VH, et al. Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility. Nat Commun 2013; 4:2854.</a></li><li><a class="nounderline abstract_t">Marjuki H, Mishin VP, Chesnokov AP, et al. Characterization of drug-resistant influenza A(H7N9) variants isolated from an oseltamivir-treated patient in Taiwan. J Infect Dis 2015; 211:249.</a></li><li><a class="nounderline abstract_t">Kile JC, Ren R, Liu L, et al. Update: Increase in Human Infections with Novel Asian Lineage Avian Influenza A(H7N9) Viruses During the Fifth Epidemic - China, October 1, 2016-August 7, 2017. MMWR Morb Mortal Wkly Rep 2017; 66:928.</a></li><li><a class="nounderline abstract_t">Ke C, Mok CKP, Zhu W, et al. Human Infection with Highly Pathogenic Avian Influenza A(H7N9) Virus, China. Emerg Infect Dis 2017; 23:1332.</a></li><li><a class="nounderline abstract_t">Adisasmito W, Chan PK, Lee N, et al. Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a Global Patient Registry. J Infect Dis 2010; 202:1154.</a></li><li><a class="nounderline abstract_t">Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus, Abdel-Ghafar AN, Chotpitayasunondh T, et al. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 2008; 358:261.</a></li><li><a class="nounderline abstract_t">Uyeki TM. Human infection with highly pathogenic avian influenza A (H5N1) virus: review of clinical issues. Clin Infect Dis 2009; 49:279.</a></li><li><a class="nounderline abstract_t">Kandun IN, Tresnaningsih E, Purba WH, et al. Factors associated with case fatality of human H5N1 virus infections in Indonesia: a case series. Lancet 2008; 372:744.</a></li><li><a class="nounderline abstract_t">Chan PK, Lee N, Zaman M, et al. Determinants of antiviral effectiveness in influenza virus A subtype H5N1. J Infect Dis 2012; 206:1359.</a></li><li><a class="nounderline abstract_t">Zheng S, Tang L, Gao H, et al. Benefit of Early Initiation of Neuraminidase Inhibitor Treatment to Hospitalized Patients With Avian Influenza A(H7N9) Virus. Clin Infect Dis 2018; 66:1054.</a></li><li><a class="nounderline abstract_t">Oner AF, Dogan N, Gasimov V, et al. H5N1 avian influenza in children. Clin Infect Dis 2012; 55:26.</a></li><li><a class="nounderline abstract_t">Liem NT, Tung CV, Hien ND, et al. Clinical features of human influenza A (H5N1) infection in Vietnam: 2004-2006. Clin Infect Dis 2009; 48:1639.</a></li><li><a class="nounderline abstract_t">Ma W, Huang H, Chen J, et al. Predictors for fatal human infections with avian H7N9 influenza, evidence from four epidemic waves in Jiangsu Province, Eastern China, 2013-2016. Influenza Other Respir Viruses 2017; 11:418.</a></li><li><a class="nounderline abstract_t">Cao B, Gao H, Zhou B, et al. Adjuvant Corticosteroid Treatment in Adults With Influenza A (H7N9) Viral Pneumonia. Crit Care Med 2016; 44:e318.</a></li><li><a class="nounderline abstract_t">Yu H, Cowling BJ, Feng L, et al. Human infection with avian influenza A H7N9 virus: an assessment of clinical severity. Lancet 2013; 382:138.</a></li><li><a class="nounderline abstract_t">Cowling BJ, Jin L, Lau EH, et al. Comparative epidemiology of human infections with avian influenza A H7N9 and H5N1 viruses in China: a population-based study of laboratory-confirmed cases. Lancet 2013; 382:129.</a></li><li><a class="nounderline abstract_t">Chen J, Wu J, Hao S, et al. Long term outcomes in survivors of epidemic Influenza A (H7N9) virus infection. Sci Rep 2017; 7:17275.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Interim guidance for infection control within healthcare settings when caring for confirmed cases, probable cases, and cases under investigation for infection with novel influenza A viruses associated with severe disease. https://www.cdc.gov/flu/avianflu/novel-flu-infection-control.htm (Accessed on June 27, 2022).</li><li class="breakAll">Prevention and antiviral treatment of bird flu viruses in people. Centers for Disease Control and Prevention. Available at: https://www.cdc.gov/flu/avianflu/prevention.htm (Accessed on June 14, 2022).</li><li><a class="nounderline abstract_t">Zhou X, Wang Y, Liu H, et al. Effectiveness of Market-Level Biosecurity at Reducing Exposure of Poultry and Humans to Avian Influenza: A Systematic Review and Meta-Analysis. J Infect Dis 2018; 218:1861.</a></li><li><a class="nounderline abstract_t">Xu J, Lu S, Wang H, Chen C. Reducing exposure to avian influenza H7N9. Lancet 2013; 381:1815.</a></li><li><a class="nounderline abstract_t">Lee SS, Wong NS, Leung CC. Exposure to avian influenza H7N9 in farms and wet markets. Lancet 2013; 381:1815.</a></li><li><a class="nounderline abstract_t">Fournié G, Pfeiffer DU. Can closure of live poultry markets halt the spread of H7N9? Lancet 2014; 383:496.</a></li><li class="breakAll">Food safety. Centers for Disease Control and Prevention. Available at: https://www.cdc.gov/foodsafety/index.html (Accessed on June 14, 2022).</li><li class="breakAll">Interim guidance on follow-up of close contacts of persons infected with novel influenza A viruses and use of antiviral medications for chemoprophylaxis. Centers for Disease Control and Prevention. Available at: https://www.cdc.gov/flu/avianflu/novel-av-chemoprophylaxis-guidance.htm (Accessed on June 13, 2022).</li><li class="breakAll">Case definitions for investigations of human infection with Avian Influenza A Viruses in the United States. Centers for Disease Control and Prevention. Available at: https://www.cdc.gov/flu/avianflu/case-definitions.html (Accessed on June 13, 2022).</li><li><a class="nounderline abstract_t">Boltz DA, Rehg JE, McClaren J, et al. Oseltamivir prophylactic regimens prevent H5N1 influenza morbidity and mortality in a ferret model. J Infect Dis 2008; 197:1315.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis--North Carolina, 2009. MMWR Morb Mortal Wkly Rep 2009; 58:969.</a></li><li><a class="nounderline abstract_t">Baz M, Abed Y, Papenburg J, et al. Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis. N Engl J Med 2009; 361:2296.</a></li><li><a class="nounderline abstract_t">Cané A, Casanueva E, Iolster T, et al. First isolation of a oseltamivir-resistant influenza A (H1N1) strain in Argentina. Pediatr Infect Dis J 2010; 29:384.</a></li></ol></div><div id="topicVersionRevision">Topic 138869 Version 5.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31668198" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Novel Avian Influenza A Virus Infections of Humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31668198" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Novel Avian Influenza A Virus Infections of Humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23726392" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16964257" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16371632" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Oseltamivir resistance during treatment of influenza A (H5N1) infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24696114" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Severe influenza A H7N9 pneumonia with rapid virological response to intravenous zanamivir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23943822" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Clinical, virological, and histopathological manifestations of fatal human infections by avian influenza A(H7N9) virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25952823" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : High-dose versus standard dose oseltamivir for treatment of severe influenza in adult intensive care unit patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21930881" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Oseltamivir and oseltamivir carboxylate pharmacokinetics in obese adults: dose modification for weight is not necessary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23723457" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29648602" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Factors Associated With Prolonged Viral Shedding in Patients With Avian Influenza A(H7N9) Virus Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35085510" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30184455" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32526195" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33302389" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Evaluation of Baloxavir Marboxil and Peramivir for the Treatment of High Pathogenicity Avian Influenza in Chickens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30837531" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Inhibition of avian-origin influenza A(H7N9) virus by the novel cap-dependent endonuclease inhibitor baloxavir marboxil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30288682" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Safety, Tolerability, and Pharmacokinetics of the Novel Anti-influenza Agent Baloxavir Marboxil in Healthy Adults: Phase I Study Findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16228009" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Avian flu: isolation of drug-resistant H5N1 virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20701864" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Oseltamivir resistance mutation N294S in human influenza A(H5N1) virus in Egypt.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25320319" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Profiling and characterization of influenza virus N1 strains potentially resistant to multiple neuraminidase inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24326875" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25124927" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Characterization of drug-resistant influenza A(H7N9) variants isolated from an oseltamivir-treated patient in Taiwan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28880856" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Update: Increase in Human Infections with Novel Asian Lineage Avian Influenza A(H7N9) Viruses During the Fifth Epidemic - China, October 1, 2016-August 7, 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28580899" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Human Infection with Highly Pathogenic Avian Influenza A(H7N9) Virus, China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20831384" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a Global Patient Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18199865" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Update on avian influenza A (H5N1) virus infection in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19522652" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Human infection with highly pathogenic avian influenza A (H5N1) virus: review of clinical issues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18706688" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Factors associated with case fatality of human H5N1 virus infections in Indonesia: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22927451" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Determinants of antiviral effectiveness in influenza virus A subtype H5N1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29077848" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Benefit of Early Initiation of Neuraminidase Inhibitor Treatment to Hospitalized Patients With Avian Influenza A(H7N9) Virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22423125" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : H5N1 avian influenza in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19435433" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Clinical features of human influenza A (H5N1) infection in Vietnam: 2004-2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28675634" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Predictors for fatal human infections with avian H7N9 influenza, evidence from four epidemic waves in Jiangsu Province, Eastern China, 2013-2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26934144" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Adjuvant Corticosteroid Treatment in Adults With Influenza A (H7N9) Viral Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23803487" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Human infection with avian influenza A H7N9 virus: an assessment of clinical severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23803488" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Comparative epidemiology of human infections with avian influenza A H7N9 and H5N1 viruses in China: a population-based study of laboratory-confirmed cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29222500" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Long term outcomes in survivors of epidemic Influenza A (H7N9) virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29222500" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Long term outcomes in survivors of epidemic Influenza A (H7N9) virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29222500" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Long term outcomes in survivors of epidemic Influenza A (H7N9) virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29986030" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Effectiveness of Market-Level Biosecurity at Reducing Exposure of Poultry and Humans to Avian Influenza: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23664060" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Reducing exposure to avian influenza H7N9.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23664058" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Exposure to avian influenza H7N9 in farms and wet markets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24183055" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Can closure of live poultry markets halt the spread of H7N9?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24183055" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Can closure of live poultry markets halt the spread of H7N9?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24183055" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Can closure of live poultry markets halt the spread of H7N9?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24183055" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Can closure of live poultry markets halt the spread of H7N9?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18422444" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Oseltamivir prophylactic regimens prevent H5N1 influenza morbidity and mortality in a ferret model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19745803" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis--North Carolina, 2009.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19907034" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20351531" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : First isolation of a oseltamivir-resistant influenza A (H1N1) strain in Argentina.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
